Table 2 Estimated objective tumor response rate at nine months.

From: Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial

Response

Imatinib only n = 36 (%)

Alternating therapy n = 40 (%)

Complete response

0 (0)

1 (3)

Partial response

22 (61)

23 (58)

Stable disease

14 (39)

15 (38)

Progressive disease

0 (0)

1 (3)

Back to article page